A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant

Trial Profile

A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Acronyms LYMRIT-37-05
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 04 Apr 2018 According to a Nordic Nanovector media release, company expects the preliminary data read-out from this study in 2H 2018.
    • 17 Mar 2017 According to a Nordic Nanovector media release, the first patient has been dosed in the study.
    • 25 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top